NEWS HIGHLIGHTS
Published Studies Related to Fosrenol (Lanthanum Carbonate)
Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trial. [2009.01]
BACKGROUND AND OBJECTIVES: Lanthanum carbonate (FOSRENOL, Shire Pharmaceuticals) is an effective noncalcium, nonresin phosphate binder for the control of hyperphosphatemia in chronic kidney disease (CKD) stage 5 patients undergoing dialysis... CONCLUSIONS: Because <1% of phosphorus is in the extracellular fluid, serum measurements may not accurately reflect total body burden in patients with CKD stages 3 and 4. However, lanthanum carbonate is an effective phosphate binder in this patient population, with a safety profile and tolerability similar to that of placebo.
Multicenter prospective randomized, double-blind comparative study between lanthanum carbonate and calcium carbonate as phosphate binders in Japanese hemodialysis patients with hyperphosphatemia. [2008.11]
BACKGROUND: The efficacy of lanthanum carbonate as a phosphate binder for the treatment of hyperphosphatemia has been reported, but not from a double-blind, comparator-controlled comparative study... CONCLUSION: Both compounds show similar efficacy on the serum phosphate level in patients undergoing hemodialysis when the dose is managed in a dose-variable and double-blind manner. However, lanthanum carbonate is superior in terms of lowering the incidence of hypercalcemia.
Effects of lanthanum carbonate on the absorption and oral bioavailability of ciprofloxacin. [2007.11]
BACKGROUND AND OBJECTIVES: Phosphate binders such as calcium salts or sevelamer, a cationic polymer, can markedly reduce absorption of oral ciprofloxacin. This randomized, open-label, two-way, crossover study examined the influence of the cation lanthanum on systemic ciprofloxacin exposure after oral administration... CONCLUSIONS: Lanthanum carbonate significantly reduces the systemic exposure to orally administered ciprofloxacin. Concomitant administration of both drugs should be avoided to prevent possible suboptimal response to ciprofloxacin.
Cognitive function in Stage 5 chronic kidney disease patients on hemodialysis: no adverse effects of lanthanum carbonate compared with standard phosphate-binder therapy. [2007.02]
Patients with Stage 5 chronic kidney disease who have hyperphosphatemia require treatment with phosphate binders to lower serum phosphorus levels. Existing binders are effective but may be associated with important safety disadvantages... Use of lanthanum carbonate as a phosphate binder does not adversely affect cognitive function compared with standard therapy.
Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up. [2006.08]
BACKGROUND: Lanthanum carbonate (LC) has been proposed as a new phosphate binder. Presented here are the results from one centre that participated in a multicentre trial to assess the effect of treatment with LC and calcium carbonate (CC) on the evolution of renal osteodystrophy in dialysis patients. Bone biopsies were performed at baseline, after 1 year of treatment and after a further 2-year follow-up period to assess the lanthanum concentration in bone and plasma... CONCLUSIONS: Bone deposition after 1 year of treatment with LC is low (highest concentration: 5.5 microg/g). There is a slow release of lanthanum from its bone deposits 2 years after the discontinuation of the treatment and no association with aluminium-like bone toxicity.
Clinical Trials Related to Fosrenol (Lanthanum Carbonate)
Conversion From Standard Phosphate Binder Therapy to Fosrenol® (Lanthanum Carbonate) in Chronic Kidney Disease Stage 5 [Terminated]
The main aim of this research study is to see if giving Fosrenol®, a chewable tablet, to
patients on haemodialysis works as well as other treatments currently used to lower blood
phosphorus levels.
Efficacy and Safety of Lanthanum Carbonate in Reducing Serum Phosphorus Levels in Subjects With Stage 3 and 4 Chronic Kidney Disease [Completed]
Chronic kidney disease (CKD) can result in a loss of ability to filter and excrete phosphate.
The body's attempt to adjust to an increased level of phosphate in the blood can result in
elevated levels of hormones and minerals resulting in serious clinical consequences. This
study is being conducted to evaluate the safety and efficacy of lanthanum carbonate in
lowering high levels of phosphorus in the blood in subjects with CKD Stages 3 and 4 compared
to placebo.
Head to Head Study Against Sevelamer Hydrochloride [Active, not recruiting]
Chewed vs. Crushed Lanthanum Carbonate in Hemodialysis Patients [Recruiting]
Patients with end-stage renal disease (ESRD) commonly develop hyperphosphatemia due to the
loss of excretory function of the kidney. This in turn may lead to the development of
secondary hyperparathyroidism (SHPT) and renal osteodystrophy. Lanthanum carbonate, a
phosphate binding agent, works by releasing lanthanum ions in the gastrointestinal tract to
bind dietary phosphate and is effective in the management of hyperphosphatemia and in
preventing secondary hyperparathyroidism.
Patients taking lanthanum carbonate as part of their phosphate binder therapy are counseled
to chew the tablets completely before swallowing, with or immediately after meals. However,
ESRD patients who are intubated or are receiving enteral tube feedings are unable to chew
the lanthanum carbonate tablets. For such patients, medications are commonly crushed and
administered through a gastrostomy tube (G-tube). Some patients may also prefer to crush the
lanthanum carbonate tablets and mix it with food instead of chewing. To date, it is not
known if crushing the lanthanum carbonate tablets prior to administration and taking it with
food will be as efficacious as chewing it.
The objective of this study is to compare the efficacy of phosphate binding between chewed
and crushed lanthanum carbonate in patients undergoing hemodialysis.
Long Term Treatment of End Stage Renal Disease Patients With Lanthanum Carbonate (Fosrenol) [Recruiting]
Patients who have been treated with Fosrenol for a minimum of 12 consecutive weeks and are
receiving dialysis will be followed for 5 years to compare mortality, bone fractures and
incidence of selected morbidities to patients with no lanthanum exposure and to patients
being treated for hyperphosphatemia with any marketed product.
|
